Akeso Advances Third ADC Candidate into Clinical Trials, Expanding Oncology Pipeline
Event summary
- Akeso's B7-H3-targeting ADC, AK157D1, cleared for Phase I trial in solid tumors by China's NMPA.
- AK157D1 is the third next-generation ADC in Akeso's pipeline, following AK146D1 and AK138D1.
- Preclinical studies show potent antitumor activity and favorable safety profile for AK157D1.
- Akeso plans to develop AK157D1 in combination with its proprietary bispecific antibodies ivonescimab and cadonilimab.
The big picture
Akeso's clearance for AK157D1 underscores its strategy of combining next-generation ADCs with proprietary bispecific antibodies to elevate treatment standards in oncology. The move aligns with broader industry trends toward targeted therapies and combination regimens, positioning Akeso as a competitive player in the global biopharmaceutical market. With over 50 innovative assets in its pipeline, Akeso is expanding its footprint in major therapeutic areas, including cancer and autoimmune diseases.
What we're watching
- Clinical Trial Progress
- The pace at which AK157D1 advances through Phase I and potential combination studies with ivonescimab and cadonilimab.
- Pipeline Differentiation
- Whether Akeso's proprietary ADC and bispecific antibody technologies can address safety limitations of first-generation ADCs.
- Commercial Strategy
- How Akeso integrates AK157D1 into its broader oncology portfolio to create next-generation standard of care.
Related topics